Abstract
Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Current Molecular Medicine
Title:Molecular Biomarkers of Anaplastic Thyroid Carcinoma
Volume: 17 Issue: 3
Author(s): F. Bozorg-Ghalati*M. Hedayati
Affiliation:
- Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Anaplastic thyroid carcinoma, molecular biomarkers, gene mutation profile, epigenetic profile, microRNA profile, cancer stem cell markers.
Abstract: Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Export Options
About this article
Cite this article as:
Bozorg-Ghalati F. *, Hedayati M. , Molecular Biomarkers of Anaplastic Thyroid Carcinoma, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170822102417
DOI https://dx.doi.org/10.2174/1566524017666170822102417 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application
Current Organic Chemistry Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets The Minority Aging Research Study: Ongoing Efforts to Obtain Brain Donation in African Americans without Dementia
Current Alzheimer Research Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry A Combination of Pharmacophore and In silico Approaches for Identification of Potential Transthyretin Amyloidosis Inhibitors
Letters in Drug Design & Discovery Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis
Current Drug Targets Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Current Topics in Medicinal Chemistry Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design The Crosstalk between Gut Microbiota, Intestinal Immunological Niche and Visceral Adipose Tissue as a New Model for the Pathogenesis of Metabolic and Inflammatory Diseases: The Paradigm of Type 2 Diabetes Mellitus
Current Medicinal Chemistry Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters TGFβ Signaling in Liver Regeneration
Current Pharmaceutical Design Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry